Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
World Tuberculosis Day: WHO goodwill ambassadors will pay attention to us!
Category:
Company News
Author:
Source:
Add time:2017-04-12 13:36
Summary:In order to raise the world's awareness of the burden of tuberculosis and the status of tuberculosis prevention and care work, and mobilize political and social commitments, the goal of global tuberculosis elimination by 2035. Therefore, March 24th is regarded as World Tuberculosis Day every year.
World Tuberculosis Day
In order to raise the world's awareness of the burden of tuberculosis and the status of tuberculosis prevention and care work, and mobilize political and social commitments, the goal of global tuberculosis elimination by 2035. Therefore, March 24th is regarded as World Tuberculosis Day every year.
Tuberculosis is one of the most serious infectious diseases in the world.
In 2016, 10.4 million new patients were diagnosed globally, and the death toll exceeded 1.8 million; for this, the world needs to spend 8 billion US dollars to prevent and control tuberculosis.
China is one of the 30 countries with a high burden of tuberculosis incidence in the world; in 2016, the number of new patients reached more than 900,000, the incidence rate ranks first in the world, and the total number of patients is third in the world.
Tuberculosis often occurs in people living in poverty. AIDS, diabetes, smoking, and alcohol all affect the high incidence of tuberculosis.
Tuberculosis is spread through droplets and air, and it is very difficult to prevent and control. A sputum-positive patient can spread 10-20 people every year.
The treatment course of tuberculosis is long, and it is difficult to distinguish between the infectious and non-infectious periods. There is no reliable preventive vaccine. The treatment cycle for tuberculosis is long; the first-line anti-tuberculosis drugs are still rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin. Except for quinolone and linezolid, no new drugs have been used in clinical treatment for initial treatment and retreatment of tuberculosis in the past 25 years; Bedaquinoline and Dramani have not been used in China. The incidence of drug-resistant tuberculosis is increasing year by year.
In 2016, it was authoritatively reported that there were more than 60,000 domestic drug-resistant patients.
The cost of treatment for drug-resistant patients is for sensitive tuberculosis patients
10 to 20 times.
The mortality rate of drug-resistant patients is more than 40%.
As one of the important manufacturers and R&D companies of anti-tuberculosis drugs in China, we are deeply responsible for our responsibility!
Shenyang Hongqi Pharmaceutical
China Anti-tuberculosis Drug Production Service Base
China Tuberculosis Association Tuberculosis Drug Supply Coordination Reserve Base
Corporate Vision: To create a world-class anti-tuberculosis drug pharmaceutical company
Corporate mission: Let humans no longer suffer from tuberculosis
Leading domestic market share:
In 2016, government procurement projects accounted for 86%;
Hospital clinical sales ranked third
(According to IMS data).
No. 1 market share of comprehensive first-line anti-tuberculosis drugs;
It is also the only company that can guarantee the supply of rifampicin, isoniazid, pyrazinamide and ethambutol at the same time.
National concern
"Thirteenth Five-Year Plan" National Tuberculosis Prevention and Control Plan
On February 1, 2017, the State Council issued the "Thirteenth Five-Year" National Tuberculosis Prevention and Control Plan. Among them, it is pointed out in the "prevention measures":
(1) Improve the prevention and treatment service system.
(2) Discover patients in multiple ways.
(3) Standardize diagnosis and treatment behavior.
(4) Do a good job in patient health management services.
(5) Do a good job of medical insurance and care and assistance.
(6) Strengthen the prevention and treatment of tuberculosis among key populations.
(7) Guarantee the supply of anti-tuberculosis drugs.
(8) Improve the level of information management.
At the same time, the Chinese government pointed out in the National Tuberculosis Prevention and Control Plan:
Our country's guiding ideology
Deepen the reform of the medical and health system, focus on patients, and improve the quality of the whole people.
Basic principles of our country
Adhere to people's health as the center, adhere to prevention first, combination of prevention and treatment, prevention and treatment according to law, scientific prevention and treatment, adhere to government organization and leadership, each department shall bear its own responsibility, the whole society shall coordinate, insist on highlighting key points, adjust measures to local conditions, categorized guidance, and steadily promote tuberculosis prevention and control strategies .
my country's planning goals
The tuberculosis prevention and control mechanism of government leadership, departmental cooperation, social collaboration, and public participation has been further improved. Disease prevention and control institutions, designated tuberculosis medical institutions, and primary medical and health institutions have a clear division of labor, and the coordinated service system has been further improved. By 2020, the incidence of tuberculosis will drop to 58/100,000.
my country's strategy and implementation
In addition to improving the tuberculosis prevention and control system and discovering patients through multiple channels, ensuring the supply of anti-tuberculosis drugs has become an important measure.
We continue to improve the quality of our products among the first-line anti-tuberculosis drugs. Through the third-phase transformation of the production line, consistency evaluation, and PQ certification, the product quality has reached the international first-class level.
We build a second-line multi-drug resistant product line through independent research and development and the introduction of agency products.
We actively participate in the "Double Thousand" poverty relief, the "Young Eagle" training program, and the "Education for the whole people on tuberculosis prevention and control" activities to actively enhance the social impact of the company;
We strengthen cooperation and exchanges in international conferences and cultivate a large number of international talents!
"Double Thousand" Operation: Let all tuberculosis patients receive timely assistance and care
March 24, 2016 is the 21st World Tuberculosis Day. my country’s propaganda theme is "Society work together to eliminate the hazards of tuberculosis". The China Anti-tuberculosis Association established the “China National Tuberculosis Public Welfare Fund” and, together with Fosun Public Welfare Foundation, and Fosun Pharma’s member company Hongqi Pharmaceutical, jointly launched the China National Tuberculosis Public Welfare Fund-Tuberculosis Poverty Relief "Double Thousand Action" project.
Peng Liyuan, Goodwill Ambassador for Tuberculosis/AIDS Prevention and Control of the World Health Organization, was invited to participate in the event, and distributed health packs to migrant workers in the city, and expressed condolences to the medical workers and migrant workers who participated in the free clinic on the spot.
The "Double Thousand Action" project started in 2016 and lasted for five years from 2020. It can save at least 1,000 poor tuberculosis patients each year, and each patient's assistance fund is at least 1,000 yuan.
The Fosun Foundation and Hongqi Pharmaceutical, a member company of Fosun Pharma, will continue to support this project and provide funds and medicines.
Fosun Pharmaceutical Group actively implements and promotes the central government’s “precise poverty alleviation and targeted poverty alleviation” decision-making and deployment, and gives full play to its advantages in the pharmaceutical and medical and health industries. Through various measures, the current focus is on poverty alleviation through industrial development, education and health. , Carry out targeted poverty alleviation work in terms of security and social poverty alleviation.
In 2016, in accordance with the overall poverty alleviation strategy of Fosun Pharmaceutical Group, a number of poverty alleviation work was carried out, and the "Double Thousand Project" was one of them. In March 2016, Fosun Pharma and Hongqi Pharmaceutical, a member company, donated 1 million yuan to the China National Tuberculosis Association through the Fosun Foundation to launch the "Double Thousand Action" project for tuberculosis poverty relief, providing funds, medicines and other forms of support.
The "Double Thousand Action" project will bring good news to poor tuberculosis patients. This is also a conscious action of Fosun Pharma to thank the society and give back to the society. As a member of the medical and health industry, Fosun Pharma is committed to helping patients, especially impoverished patients, receive timely assistance, so that they can regain a healthy and happy life. In the future, Fosun Pharma will continue to pay attention to and support China's anti-tuberculosis cause.
